Neutrophils as Possible Therapeutic Targets in Severe Influenza Pneumonia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Neutrophil subsets and their differential roles in viral respiratory diseases.Journal of leukocyte biology · 2022
   Review
2. Neutrophil to CD4+ lymphocyte ratio as a potential biomarker in predicting virus negative conversion time in COVID-19.International immunopharmacology · 2020
   Article
3. Neutrophils-related host factors associated with severe disease and fatality in patients with influenza infection.Nature communications · 2019
   Article
4. Understanding the role of host response in influenza pneumonitis.Intensive care medicine · 2019
   Article
5. Neutrophil-lymphocyte ratio as an early new marker in AIV-H7N9-infected patients: a retrospective study.Therapeutics and clinical risk management · 2019
   Article
6. The Role of Extracellular Histones in Influenza Virus Pathogenesis.The American journal of pathology · 2018
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.